235 related articles for article (PubMed ID: 12648581)
1. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract][Full Text] [Related]
2. The role of p53 mutation in the carcinomas arising from endometriosis.
Akahane T; Sekizawa A; Purwosunu Y; Nagatsuka M; Okai T
Int J Gynecol Pathol; 2007 Jul; 26(3):345-51. PubMed ID: 17581423
[TBL] [Abstract][Full Text] [Related]
3. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma.
Otsuka J; Okuda T; Sekizawa A; Amemiya S; Saito H; Okai T; Kushima M; Tachikawa T
Med Electron Microsc; 2004 Sep; 37(3):188-92. PubMed ID: 15449112
[TBL] [Abstract][Full Text] [Related]
4. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
[TBL] [Abstract][Full Text] [Related]
5. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
[TBL] [Abstract][Full Text] [Related]
6. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
7. Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
Willner J; Wurz K; Allison KH; Galic V; Garcia RL; Goff BA; Swisher EM
Hum Pathol; 2007 Apr; 38(4):607-13. PubMed ID: 17258789
[TBL] [Abstract][Full Text] [Related]
8. Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis.
Xu B; Hamada S; Kusuki I; Itoh R; Kitawaki J
Gynecol Oncol; 2011 Feb; 120(2):239-46. PubMed ID: 21130491
[TBL] [Abstract][Full Text] [Related]
9. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract][Full Text] [Related]
10. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
11. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
Kolasa IK; Rembiszewska A; Janiec-Jankowska A; Dansonka-Mieszkowska A; Lewandowska AM; Konopka B; Kupryjańczyk J
Gynecol Oncol; 2006 Nov; 103(2):692-7. PubMed ID: 16793127
[TBL] [Abstract][Full Text] [Related]
12. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
13. Steroid sulfatase expression in ovarian clear cell adenocarcinoma: immunohistochemical study.
Okuda T; Saito H; Sekizawa A; Shimizu Y; Akamatsu T; Kushima M; Yanaihara T; Okai T; Farina A
Gynecol Oncol; 2001 Sep; 82(3):427-34. PubMed ID: 11520136
[TBL] [Abstract][Full Text] [Related]
14. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
[TBL] [Abstract][Full Text] [Related]
15. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Barreta A; Sarian LO; Ferracini AC; Costa LBE; Mazzola PG; de Angelo Andrade L; Derchain S
Hum Pathol; 2019 Mar; 85():72-81. PubMed ID: 30447298
[TBL] [Abstract][Full Text] [Related]
17. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
[TBL] [Abstract][Full Text] [Related]
18. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
19. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
20. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
